Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia

Diabetologia

Volumn 50, Issue 1, 2007, Pages 142-150

  Conarello, S L ^a   Jiang, G ^a   Mu, J ^a   Li, Z ^a   Woods, J ^a   Zycband, E ^a   Ronan, J ^a   Liu, F ^a   Roy, R Sinha ^a   Zhu, L ^a   Charron, M J ^b   Zhang, B B ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Beta cell; Gene knockout; Glucagon receptor; Metabolic control

Indexed keywords

GLUCAGON RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL DAMAGE; CELL LOSS; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; EXPERIMENTAL DIABETES MELLITUS; FATTY LIVER; FOOD INTAKE; GENE; GENE DELETION; GLUCAGON RECEPTOR GENE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE TOLERANCE; GLUCOSE TOLERANCE TEST; HISTOLOGY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERLEPTINEMIA; KNOCKOUT GENE; KNOCKOUT MOUSE; LIPID DIET; MALE; METABOLIC REGULATION; MOUSE; NONHUMAN; OBESITY; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; STOMACH EMPTYING; STREPTOZOCIN DIABETES; WILD TYPE;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DIETARY FATS; DISEASE MODELS, ANIMAL; GENE DELETION; GLUCOSE; HOMEOSTASIS; HYPERGLYCEMIA; INSULIN-SECRETING CELLS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OBESITY; RECEPTORS, GLUCAGON; STREPTOZOCIN;

EID: 33845919110     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-006-0481-3     Document Type: Article

References (38)

1. Jiang G, Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671-E678
2. Burcelin R, Katz EB, Charron MJ (1996) Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Diabetes Metab 22:373-396
3. Toft I, Gerich JE, Jenssen T (2002) Autoregulation of endogenous glucose production during hyperglucagonemia. Metabolism 51:1128-1134
4. Unger RH (1985) Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 28:574-578
5. Consoli A (1992) Role of liver in pathophysiology of NIDDM. Diabetes Care 15:430-441
6. Basu A, Alzaid A, Dinneen S, Caumo A, Cobelli C, Rizza RA (1996) Effects of a change in the pattern of insulin delivery on carbohydrate tolerance in diabetic and nondiabetic humans in the presence of differing degrees of insulin resistance. J Clin Invest 97:2351-2361
7. Butler PC, Rizza RA (1991) Contribution to postprandial hyperglycaemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40:73-81
8. Larsson H, Ahren B (2000) Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 23:650-657
9. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA (2000) Lack of suppression of glucagon contributes to postprandial hyperglycaemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 85:4053-4059
10. Zhang BB, Moller DE (2000) New approaches in the treatment of type 2 diabetes. Curr Opin Chem Biol 4:461-467
11. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD (2002) Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 290:839-843
12. Gelling RW, Du XQ, Dichmann DS et al (2003) Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 100:1438-1443
13. Brand CL, Jorgensen PN, Knigge U et al (1995) Role of glucagon in maintenance of euglycaemia in fed and fasted rats. Am J Physiol 269:E469-E477
14. Brand CL, Jorgensen PN, Svendsen I, Holst JJ (1996) Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45:1076-1083
15. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ (1994) Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37:985-993
16. Liang Y, Osborne MC, Monia BP et al (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53:410-417
17. Sloop KW, Cao JX, Siesky AM et al (2004) Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113:1571-1581
18. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D (1982) Hyperglycaemia of diabetic rats decreased by a glucagon receptor antagonist. Science 215:1115-1116
19. Unson CG, Gurzenda EM, Merrifield RB (1989) Biological activities of des-His1[Glu9]glucagon amide, a glucagon antagonist. Peptides 10:1171-1177
20. Van Tine BA, Azizeh BY, Trivedi D et al (1996) Low level cyclic adenosine 3′,5′-monophosphate accumulation analysis of [des-His1, des-Phe6, Glu9] glucagon-NH2 identifies glucagon antagonists from weak partial agonists/antagonists. Endocrinology 137:3316-3322
21. Ling A, Hong Y, Gonzalez J et al (2001) Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 44:3141-3149
22. Ling A, Plewe M, Gonzalez J et al (2002) Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 12:663-666
23. Petersen KF, Sullivan JT (2001) Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44:2018-2024
24. Qureshi SA, Rios Candelore M, Xie D et al (2004) A novel glucagon receptor antagonist inhibits glucagon-mediated biological effects. Diabetes 53:3267-3273
25. Dallas-Yang Q, Shen X, Strowski M et al (2004) Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 501:225-234
26. Shen DM, Zhang F, Brady EJ et al (2005) Discovery of novel, potent, and orally active spiro-urea human glucagon receptor antagonists. Bioorg Med Chem Lett 15:4564-4569
27. Baggio LL, Drucker DJ (2002) Harnessing the therapeutic potential of glucagon-like peptide-1: a critical review. Treat Endocrinol 1:117-125
28. Walaas O, Walaas E (1950) Effect of epinephrine on rat diaphragm. J Biol Chem 187:769-776
29. Fujita Y, Kojima H, Hidaka H, Fujimiya M, Kashiwagi A, Kikkawa R (1998) Increased intestinal glucose absorption and postprandial hyperglycaemia at the early step of glucose intolerance in Otsuka Long-Evans Tokushima Fatty rats. Diabetologia 41:1459-1466
30. D'Alessio DA, Vogel R, Prigeon R et al (1996) Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons. J Clin Invest 97:133-138
31. Ehrenpreis ED, Salvino M, Craig RM (2001) Improving the serum D-xylose test for the identification of patients with small intestinal malabsorption. J Clin Gastroenterol 33:36-40
32. Drucker DJ (2001) Minireview: the glucagon-like peptides. Endocrinology. 142:521-527
33. Nakade Y, Tsukamoto K, Pappas TN, Takahashi T (2006) Central glucagon like peptide-1 delays solid gastric emptying via central CRF and peripheral sympathetic pathway in rats. Brain Res 1111:117-121
34. Nauck MA, Holst JJ, Willms B, Schmiegel W (1997) Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 105:187-195
35. Hippen AR (2000) Glucagon as a potential therapy for ketosis and fatty liver. Vet Clin North Am Food Anim Pract 16:267-282
36. Hippen AR, She P, Young JW et al (1999) Alleviation of fatty liver in dairy cows with 14-day intravenous infusions of glucagon. J Dairy Sci 82:1139-1152
37. Conarello SL, Li Z, Ronan J et al (2003) Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Natl Acad Sci USA 100:6825-6830
38. Pospisilik JA, Martin J, Doty Tet al (2003) Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52:741-750